Harmony Biosciences Holdings, Inc. (HRMY) saw its stock price soar 5.28% during intraday trading on Tuesday. The significant upward movement followed the company's release of its fourth-quarter and full-year 2025 financial results before the market opened.

The pharmaceutical company reported Q4 net product revenue of $243.78 million, surpassing the IBES consensus estimate of $240.4 million and representing a 21% year-over-year increase. The revenue growth was primarily driven by strong demand for its narcolepsy treatment, WAKIX. Furthermore, Harmony Biosciences reiterated its 2026 net revenue guidance for WAKIX, projecting it to reach between $1.0 billion and $1.04 billion, which would achieve blockbuster status for the drug.

While the company reported a decline in adjusted net income for the quarter, the market's positive reaction appears focused on the robust top-line performance and the confident outlook for its flagship product. The reiterated multi-billion dollar revenue target for the coming year signals management's expectation of sustained commercial strength and growth potential.